ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2

preprint
submitted on 08.09.2020, 21:23 and posted on 09.09.2020, 09:52 by Vijayagopal Gopalsamuthiram, Corshai Williams, Jeffrey Noble, Timothy F. Jamison, B. Frank Gupton, David Snead
A new route to MK-4482 (1) was developed. The route replaces uridine with the more available and less expensive cytidine. Low cost, simple reagents are used for the chemical transformations and the yield is improved from 17% to 44%. A step is removed from the longest linear sequence, and these advancements are expected to expand access to MK-4482 should it become a viable drug substance.

Funding

The Bill and Melinda Gates Foundation

History

Email Address of Submitting Author

drsnead@vcu.edu

Institution

Virginia Commonwealth University

Country

USA

ORCID For Submitting Author

0000-0001-7839-452X

Declaration of Conflict of Interest

No conflict of interest

Exports